NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Friday, S ...

The company didn't quite meet expectations for either trailing results or full-year guidance. Cancer drug developer Y-mAbs Therapeutics (YMAB -11.24%) didn't exactly kick off the stock trading week on a high note. The company's shares closed the day more than 11% lower in price, following the release of its latest set of quarterly results. That contrasted unfavorably with the performance of the bellwether S&P 500 index, which flatlined that session. A double miss for the second quarter Y-mAbs is a commercia ...

simonkr Topline Summary and Update Y-mAbs Therapeutics (NASDAQ:YMAB) has maintained something of a holding pattern in terms of market valuation after my last article published in May 2024. Now, we've seen some updates coming out of summer meetings, as well as new financial filings for the company. Still sitting at a market cap of nearly $500 million, YMAB continues to be priced in line with a mid-stage clinical biotech, as opposed to being a commercial-stage entity, and today I want to take a look to see if ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Nicole Germino - Truist Securities Justin Walsh - JonesTrading Alec Stranahan - Bank of America Michael Ulz - Morgan Stanley John Newman - Canaccord Genuity Operator Good ...

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%. Over the last four quarters, the company h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State or other ...

Exhibit 99.1 Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase ● Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong ● Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter ...

Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024 Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...